Clinical trials: Measurable Residual Disease
Neoplasms, Solid Tumor
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict…
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms
- Trial name
- METHYLSCAPE-CO (NCT07741435)
- Testing
- Methylscape DNA methylation assay
- Where
- Colombia
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose.
- Trial name
- NCT05536700
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cancer, Early Detection of Cancer
Caris Biorepository Research Protocol
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for…
- Conditions
- Cancer, Early Detection of Cancer, Minimal Residual Disease
- Trial name
- NCT01499394
- Where
- 38 sites in United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Caris Science, Inc.
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Minimal Residual Disease, Fertility Preservation
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors
For prepubertal patients, cryopreservation of ovarian tissue is the only option available to preserve their fertility before cancer treatment.
- Trial name
- OVAMAR (NCT02400827)
- Testing
- malignant cells
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Pre B ALL, Regulatory T Cell
The Effect of Chemotherapy on Regulatory T Cells
The investigators aimed to study the effect of chemotherapy on regulatory T cells (Tregs) in children with precursor B (PreB) acute lymphoblastic leukemia (ALL) at 15 and 33 days of malignity directed therapy.
- Trial name
- NCT03413046
- Testing
- Peripheral and bone marrow sampling
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital
Myeloma Multiple
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
- Trial name
- NCT05091372
- Testing
- Belantamab mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia ALL
Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia
Minimal residual disease (MRD) monitoring is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Currently, MRD assessment relies mainly on cellular DNA obtained from bone marrow aspirates.
- Trial name
- CIRCALL (NCT07483476)
- Testing
- Biological sample collection
- Where
- 2 sites in France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CLL, SLL
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or…
- Conditions
- CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia
- Trial name
- NCT04694560
- Testing
- Treatment Free Observation
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory
Multiple Myeloma
ctDNA Methylation Sequencing for Myeloma
1. To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods…
- Trial name
- NCT05578625
- Testing
- plasma circulation DNA methylation sequencing
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China